Valeant Pharmaceuticals Intl Inc. May Not Be an Enron, But Trouble Lies Ahead

Now is not the time to own Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

| More on:
The Motley Fool

Last week, shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) plunged after short-seller Andrew Left suggested the company could be a “pharmaceutical Enron.” He pointed to Valeant’s relationship with a specialty pharmacy called Philidor, and then noted Philidor’s relationship to a small Californian pharmacy called R&O.

Mr. Left then suggested that Valeant was “stuffing the channel” by selling product to R&O and similar pharmacies, then falsely booking the transaction as revenue.

Fortunately for the company, Mr. Left is an easy target. He is very brash during interviews. His report has a sensationalized tone, which includes the repeated use of red bold letters. He has an imperfect past, which includes sanctions from the National Futures Association. And while he has uncovered some very suspicious activity, the notion that Valeant is stuffing the channel remains very speculative.

As would be expected, Valeant has focused its defence on Mr. Left. The company has even asked the Securities and Exchange Commission to investigate him. Valeant has also strongly denied the channel-stuffing accusations.

But here’s the problem: Mr. Left isn’t the only one doing some digging on Valeant—others include the Southern Investigative Reporting Foundation, Bronte Capital, The New York Times, and The Wall Street Journal. And compared to these other outfits, Mr. Left has only scratched the surface.

Suspicious activity

This story is a very complicated one, but I will try to simplify it for you. Late last year, Valeant paid US$100 million to Philidor for an option to acquire the company for $0. This should already raise some red flags—after all, why purchase such an option when you can simply buy the company instead?

It also seems that Valeant has tight control over Philidor’s operations. An article in The Wall Street Journal claims that Valeant went to great lengths to conceal this arrangement—some employees even used fake names.

Meanwhile, it seems that Philidor is essentially selling pharmaceuticals in California (and elsewhere) through R&O. This is significant because Philidor was denied a license to sell drugs in California back in May 2014.

What does this mean?

Here’s the good news for Valeant shareholders: there is still no evidence of channel stuffing. So, for now it is still inappropriate to call Valeant the “pharmaceutical Enron.”

But there’s plenty of bad news. Philidor’s actions appear fraudulent, and the problems concern sales all over the United States, not just in the state of California. The potential penalties against the company are massive.

Valeant maintains that since it technically doesn’t own Philidor, it cannot be held liable for these issues. This is probably why Valeant purchased an option rather than purchase Philidor outright.

But if The Wall Street Journal’s report is true, then Valeant could find itself in deep trouble with regulators, insurers, and pharmacy-benefit managers. This case is far from over, and you should certainly not own any Valeant stock in the meantime.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

money cash dividends
Stocks for Beginners

Where to Invest $10,000 in April 2024

If you've already created a diversified portfolio and are looking for more options from a windfall, here is where I…

Read more »

data analyze research
Investing

The Ultimate TSX Stock to Buy With $1,000 Right Now

Brookfield Asset Management (TSX:BAM) is one of the best Canadian stocks to buy for those looking to put capital to…

Read more »

young woman celebrating a victory while working with mobile phone in the office
Dividend Stocks

3 CRA Benefits Most Canadians Can Grab in 2024

You can save on taxes by claiming the dividend tax credit on Fortis Inc (TSX:FTS) shares.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

young woman celebrating a victory while working with mobile phone in the office
Investing

3 Roaring Stocks to Hold for the Next 20 Years

These top TSX stocks are excellent long-term buys, given their multi-year growth potential and solid underlying businesses.

Read more »

Two seniors float in a pool.
Dividend Stocks

TFSA: How to Earn $1,890 in Annual Tax-Free Income

Plunk these investments into your TFSA to earn passive income and avoid the taxman.

Read more »

grow dividends
Investing

Here’s My Top 3 TSX Stocks to Buy Right Now

Even though the TSX has been rising, there are still some good bargains out there. Here are three top compounding…

Read more »

Target. Stand out from the crowd
Investing

Prediction: This Canadian Growth Stock Could Double by 2030

Alimentation Couche-Tard (TSX:ATD) is a top growth stock that could do well over the next six or so years.

Read more »